重要新闻提示 上纬新材（688585）：核查结束，今日复牌 1. 中国人民银行8月4日消息，新修订的反洗钱法于2025年1月1日起正式施行，为落实反洗钱法有关要 求，有效应对反洗钱国际评估，中国人民银行会同国家金融监督管理总局、中国证券监督管理委员会起 草了《金融机构客户尽职调查和客户身份资料及交易记录保存管理办法（征求意见稿）》，现向社会公 开征求意见。意见反馈截止时间为2025年9月3日。管理办法规范的主要内容包括：明确客户尽职调查总 体要求。完善客户尽职调查具体要求。完善适用范围等内容，确保与反洗钱法相衔接。 2. 8月4日，中国人民银行发布2025年7月中央银行各项工具流动性投放情况。数据显示，7月，常备借贷 便利（SLF）净回笼3亿元，中期借贷便利（MLF）净投放1000亿元，抵押补充贷款（PSL）净回笼 2300亿元，短期逆回购净投放1880亿元，买断式逆回购净投放2000亿元。7月没有开展公开市场国债买 卖。 中国船舶、中国重工：披露中国船舶换股吸收合并中国重工事项异议股东收购请求权实施公告。中国船 舶股票8月13日起连续停牌；中国重工股票8月13日起连续停牌，直至终止上市，不再复牌。 天坛生物 ...

今日晚间，天坛生物公告称，公司收到控股股东中国生物《关于投资商业机会的通知函》，由于派林生 物主营业务为血液制品的研究、开发、生产和销售，与公司主营业务构成同业竞争，中国生物根据2017 年12月1日出具的前次避免同业竞争承诺函，将其获得的与公司主营业务构成实质性同业竞争的新业务 机会书面通知公司。 面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 智通财经8月4日讯（记者 何凡 卢阿峰）由于天坛生物（600161.SH）、派林生物（000403.SZ）在主营 业务构成同业竞争，前者拟放弃收购派林生物控股股东胜帮英豪持有的其全部21.03%股份一事（以下 简称"商业机会"），此后，天坛生物控股股东中国生物将实施派林生物商业机会的收购。 若公司直接收购派林生物控股权，公司需直接承担历史业务整合不完全、收购后经营整合过程中导致的 业务波动风险以及标的公司可能存在的其他潜在风险。如果选择由中国生物先进行收购，可以促使双方 在战略规划、资源调配、 ...

天坛生物（600161）(600161.SH)发布公告，近期，公司收到控股股东中国生物《关于投资商业机会的 通知函》，本次交易标的为派林生物（000403）控股股东胜帮英豪持有的其全部21.03%股份(简称"商业 机会")。由于派林生物主营业务为血液制品的研究、开发、生产和销售，与公司主营业务构成同业竞 争，中国生物根据2017年12月1日出具的《关于避免与北京天坛生物制品股份有限公司同业竞争的承诺 函》(简称"前次避免同业竞争承诺函")，将其获得的与公司主营业务构成实质性同业竞争的新业务机会 书面通知公司。 经审慎分析研判，公司拟放弃收购派林生物商业机会。公司放弃收购派林生物商业机会后，中国生物将 从整体发展战略出发，实施派林生物商业机会的收购，中国生物完成本次收购后，将就新增同业竞争问 题的解决时限、基本路径等做出进一步承诺，公司将在收到相关承诺文件后及时履行信息披露义务。中 国生物已根据前次避免同业竞争承诺函，及时向公司书面告知商业机会，已履行承诺函中的义务，不存 在违反承诺的情形。 ...

人民财讯8月4日电，天坛生物（600161）8月4日晚间公告，近期，公司收到控股股东中国生物《关于投 资商业机会的通知函》，本次交易标的为派林生物（000403）控股股东胜帮英豪持有的其全部21.03% 股份(简称"商业机会")。由于派林生物主营业务为血液制品的研究、开发、生产和销售，与公司主营业 务构成同业竞争，中国生物根据2017年12月1日出具的《关于避免与北京天坛生物制品股份有限公司同 业竞争的承诺函》，将其获得的与公司主营业务构成实质性同业竞争的新业务机会书面通知公司。经审 慎分析研判，公司拟放弃收购派林生物商业机会。公司放弃收购派林生物商业机会后，中国生物将从整 体发展战略出发，实施派林生物商业机会的收购，中国生物完成本次收购后，将就新增同业竞争问题的 解决时限、基本路径等做出进一步承诺。 ...

Group 1 - The A-share biopharmaceutical sector experienced a short-term surge, with Tian Tan Biological reaching the daily limit, and Wan Ze Shares previously hitting the limit as well [1] - Other companies such as Aidi Pharmaceutical, Zhifei Biological, Boya Biological, Bohui Innovation, and Pailin Biological also saw increases in their stock prices [1] - The news is driven by the completion of China's first copy-type Tian Tan smallpox vaccine carrier HIV vaccine Phase I clinical trial by teams from the Chinese Center for Disease Control and Prevention and the AIDS Prevention Center [1]

Group 1 - The biopharmaceutical sector experienced a short-term surge, with TianTan Bio reaching the daily limit increase [1] - WanZe Co. previously hit the limit up, indicating strong market interest [1] - Other companies such as Aidi Pharmaceutical, ZhiFei Biological, BoYa Bio, BoHui Innovation, and PaiLin Bio also saw significant gains [1]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for secretaries in the A-share biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] Age and Education Distribution - The age distribution of secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those aged 30-40 make up 18% [1] - In terms of education, 52% of secretaries hold a bachelor's degree, while 44% have a master's degree, and only 2% possess a doctoral degree [3] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the highest number of investor meetings are: Bohui Innovation (1,500 meetings), Jindike (777 meetings), Nearshore Protein (681 meetings), Sailun Biotech (549 meetings), and Kanghua Biotech (504 meetings) [9]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries among company secretaries is as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 make up 61%, while those over 50 account for 15%, and those aged 30-40 account for 18% [1] - In terms of education, 52% of company secretaries hold a bachelor's degree, while 44% have a master's degree, and only 2% have a doctoral degree [3] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the highest number of investor meetings are: Bohui Innovation (1,500 meetings), Jindike (777 meetings), Nearshore Protein (681 meetings), Sailun Biotech (549 meetings), and Kanghua Biotech (504 meetings) [9]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for company secretaries in the biopharmaceutical sector is 1.01 million yuan, with the distribution of salaries as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] - The top five highest-paid company secretaries have salaries of 3.2565 million yuan, 2.5345 million yuan, 2.2809 million yuan, 1.9265 million yuan, and 1.89 million yuan, with their tenure at the companies ranging from less than one year to 15 years [7] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those under 30 make up 6% [1][3] - The educational background indicates that 52% hold a bachelor's degree, 44% have a master's degree, and only 2% possess a doctoral degree, with the latter represented by just one individual [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually, while only 2% have more than 1,000 meetings [9] - The five companies with the highest number of investor meetings are reported to have 1,500, 777, 681, 549, and 504 meetings, respectively [9]

Group 1 - The company has raised a total of RMB 1,577,739,984.00 through a private placement of 48,004,800 shares at a price of RMB 33.33 per share, with a net amount of RMB 1,575,241,979.20 after deducting issuance costs [1][2] - The company has established a special account for the management and use of the raised funds, ensuring compliance with relevant laws and regulations [2][3] - The company has signed multiple regulatory agreements with various banks and its sponsor to ensure proper oversight of the raised funds [3] Group 2 - The company has completed the investment projects funded by the raised capital, including the "New and Relocated Plasma Collection Station Project" and "Information Technology Construction Project" [4] - A total of RMB 4.0496 million from the special account has been transferred to other fundraising accounts, and the company has initiated the closure of certain fundraising accounts [4][5] - The closure of the fundraising accounts has been communicated to the sponsor and relevant parties, and the associated regulatory agreements have been terminated [4][5]